Lyell Immunopharma (LYEL) Gains from Sales and Divestitures (2021)
Lyell Immunopharma recorded quarterly Gains from Sales and Divestitures of $4.0 million in Q3 2021, up 32.57% quarter-over-quarter from $3.0 million in Q2 2021.
Lyell Immunopharma's Gains from Sales and Divestitures history runs 1 years deep, the most recent figure standing at $4.0 million for Q3 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 3.97 Mn |
| Sep 30, 2021 | 3.97 Mn |
| Jun 30, 2021 | 2.99 Mn |
| Jun 30, 2021 | 2.99 Mn |